Merck seeks FDA approval to use Gardasil for boys; Emergent backs away from Protein Sciences;

Vaccine Market

In a long anticipated move, Merck has filed an application with the FDA to approve the use of Gardasil to guard boys against the human papillomavirus. Merck got an approval for Gardasil in girls in 2006 and has since seen it go on to become one of its most successful vaccines. Report

After spending months in a bitter takeover battle, Emergent BioSolutions says it's giving up on a proposed $78 million merger with Protein Sciences. Story

The U.S. vaccine subsidiary of Sanofi Pasteur spent $565,000 in the third quarter lobbying the U.S. government on a range of issues that included vaccine safety funding, children's vaccines and pandemic concerns. Report

A serious flu outbreak has hit the U.K., but health officials say that the number of cases may have peaked before it hit epidemic proportions. Report

Vaccine Research

Shares of Cytos Biotechnology jumped at the beginning of the week after Pfizer announced that it would take commercial licenses for vaccines based on Cytos' immunodrug technology. Story

Commonly used pneumococcal polysaccharide vaccines do not appear to be effective for preventing pneumonia, according to a study by a team of researchers from Switzerland and the United Kingdom. Release

A new study reports that the hepatitis A vaccine can guard against infections for 10 years. Report

CureVac today announced that it has received FDA approval to begin a Phase I/IIa clinical study with CV9103. The mRNA vaccine will be tested in patients with hormone-refractory metastatic prostate cancer. CureVac release